Develops and commercialises clinically meaningful novel therapeutics for children, focusing on a humanised anti‑GD2 monoclonal antibody (Hu14.18) for newly diagnosed high‑risk neuroblastoma. Phase II data showed outstanding outcomes when Hu14.18 was added to induction chemotherapy (3‑year EFS 73.7%, OS 86.0%); seeks industry collaborations across manufacturing, formulation, research and investment.